INTERLEUKIN-1 STIMULATES THE EXPRESSION OF TYPE-I AND TYPE-II INTERLEUKIN-1 RECEPTORS IN THE RAT INSULINOMA CELL-LINE RINM5F - SEQUENCING A RAT TYPE-II INTERLEUKIN-1 RECEPTOR CDNA

被引:0
作者
BRISTULF, J
GATTI, S
MALINOWSKY, D
BJORK, L
SUNDGREN, AK
BARTFAI, T
机构
[1] UNIV STOCKHOLM, DEPT NEUROCHEM & NEUROTOXICOL, ARRHENIUS LABS NAT SCI, S-10691 STOCKHOLM, SWEDEN
[2] UNIV STOCKHOLM, DEPT IMMUNOL, ARRHENIUS LABS NAT SCI, S-10691 STOCKHOLM, SWEDEN
关键词
INTERLEUKIN-1; RECEPTOR; RAT; PANCREAS; DIABETES; TNF-ALPHA;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The insulin secreting rat Rinm5F cells are often used to study the cytotoxic actions of interleukin-1 (IL-1) on pancreatic beta-cells. We demonstrate here that Rinm5F insulinoma cells express both type I and type II interleukin-1 receptor (IL-1R) mRNAs and gene products. IL-IR agonists, recombinant murine IL-1 alpha (rmIL-1 alpha, 10 ng/ml) and recombinant rat IL-1 beta (rrIL-1 beta, 100 pg/ml or 10 ng/ml) induce the upregulation of mRNA expression for both types of IL-1 receptors (IL-1Rs). This effect of rrIL-1 beta is antagonised by preincubation with recombinant human interleukin 1 receptor antagonist protein (rhIL-1ra, 5 mu g/ml). Furthermore, this rrIL-1 beta induced upregulation of IL-1R mRNAs is blocked by actinomycin D (7.5 mu g/ml), whereas cycloheximide (20 mu g/ml) has no effect. The phorbol ester PMA (20 nM) upregulates the expression of mRNAs both IL-1 receptors, whereas glucose (50 mM) upregulates the expression of the type I IL-1R mRNA only. Pretreatment of cells with pertussis toxin (100 ng/ml) partially blocks the rrIL-1 beta induced expression of mRNA for the type I and, to a lesser extent, the type II IL-1R. Incubation of the cells with rrIL-1 beta also induces a time-dependent expressionof c-fos, interleukin-6 (IL-6) and tumour necrosis factor alpha. (TNF-alpha) mRNAs. Binding studies with I-125-recombinant human IL-1 beta (I-125-rhIL-1 beta) indicate that IL-1R gene products, with the ligand binding characteristics of the type I IL-1R, are constitutively present on Rinm5F cells. Treatment with rrIL-1 beta (6h) increases the number of I-125-rhIL-1 beta binding sites on Rinm5F cells. We have also demonstrated that the number of type II IL-1R binding sites increases after induction with rrIL-1 beta (6h), by indirect immunofluorescence using a monoclonal antibody (ALVA 42) raised against the human type II IL-1R. Furthermore, we have sequenced the type II IL-1R cDNA in the rat insulinoma Rinm5F cells. The comparison of the amino acid sequence of the rat type II IL-1R with that of the mouse and human type II IL-1Rs shows 90% and 62% amino acid identity, respectively. The most important difference between the human and murine type II IL-1Rs, and this rat type II IL-1R cDNA, is an open reading frame coding for a six amino acid longer, strongly charged (QIKEMK), cytosolic domain. Another detected difference is a putative longer signal sequence in the rat type II IL-1R, as compared to human and murine cDNA.
引用
收藏
页码:319 / 330
页数:12
相关论文
共 50 条
  • [41] In vitro and in vivo study of regulation mechanisms of type I interleukin-1 receptor
    Takii, T
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2001, 121 (01): : 9 - 21
  • [42] Involvement of interleukin-1 type 1 receptors in lipopolysaccharide-induced sickness responses
    Matsuwaki, Takashi
    Shionoya, Kiseko
    Ihnatko, Robert
    Eskilsson, Anna
    Kakuta, Shigeru
    Dufour, Sylvie
    Schwaninger, Markus
    Waisman, Ari
    Mueller, Werner
    Pinteaux, Emmanuel
    Engblom, David
    Blomqvist, Anders
    BRAIN BEHAVIOR AND IMMUNITY, 2017, 66 : 165 - 176
  • [43] Cell type-specific interleukin-1β signaling in the CNS
    Srinivasan, D
    Yen, JH
    Joseph, DJ
    Friedman, W
    JOURNAL OF NEUROSCIENCE, 2004, 24 (29) : 6482 - 6488
  • [44] Effects of interleukin-1 receptor antagonist in a slow-release hylan vehicle on rat type II collagen arthritis
    Bendele, A
    McAbee, T
    Woodward, M
    Scherrer, J
    Collins, D
    Frazier, J
    Chlipala, E
    McCabe, D
    PHARMACEUTICAL RESEARCH, 1998, 15 (10) : 1557 - 1561
  • [45] The remedial effect of soluble interleukin-1 receptor type II on endometriosis in the nude mouse model
    Gao, Liying
    Sun, Liang
    Cui, Yugui
    Hou, Zhen
    Gao, Li
    Zhou, Jing
    Mao, Yundong
    Han, Suping
    Liu, Jiayin
    JOURNAL OF BIOMEDICAL RESEARCH, 2010, 24 (01): : 43 - 50
  • [46] INTERLEUKIN-1-INDUCED ACTIVATION OF A PROTEIN-KINASE CO-PRECIPITATING WITH THE TYPE-I INTERLEUKIN-1 RECEPTOR IN T-CELLS
    MARTIN, M
    BOL, GF
    ERIKSSON, A
    RESCH, K
    BRIGELIUS-FLOHE, R
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (07) : 1566 - 1571
  • [47] Three Promoters Regulate Tissue- and Cell Type-specific Expression of Murine Interleukin-1 Receptor Type I
    Chen, Qun
    Zhang, Hao
    Li, Qiming
    An, Ying
    Herkenham, Miles
    Lai, Wenmin
    Popovich, Phillip
    Agarwal, Sudha
    Quan, Ning
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (13) : 8694 - 8704
  • [48] INTERLEUKIN-1 RECEPTORS ON HUMAN THYROID-CELLS AND ON THE RAT-THYROID CELL-LINE FRTL-5
    SVENSON, M
    KAYSER, L
    HANSEN, MB
    RASMUSSEN, AK
    BENDTZEN, K
    CYTOKINE, 1991, 3 (02) : 125 - 130
  • [49] Inhibition of interleukin-1 type I receptor expression in human cell-lines by an antisense phosphorothioate oligodeoxynucleotide
    Miraglia, L
    Geiger, T
    Bennett, CF
    Dean, NM
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1996, 18 (04): : 227 - +
  • [50] Immunohistochemical analysis of interleukin-1α, its type I receptor and antagonist in keratocystic odontogenic tumors
    Suyama, Yoko
    Kubota, Yasutaka
    Ninomiya, Tomohiro
    Shirasuna, Kanemitsu
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2008, 37 (09) : 560 - 564